Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors

• DOI: 10.1007/s00280-020-04189-8
• Publication Date: 2020-11-10T05:15:24Z
• Authors: Timothy Crook; Andrew Gaya; Raymond Page; Sewanti Limaye; Anantbhushan Ranade; Amit Bhatt; Sanket Patil; Prashant Kumar; Darshana Patil; Dadasaheb Akolkar
• Keywords: Solid tumor

Selection of cytotoxic chemotherapy agents (CCA) based on pre-treatment evaluation drug sensitivities is a desirable but unmet goal for personalized anticancer treatment strategies. Prior attempts to correlate in vitro Chemo-Response Profiles (CRP) tumor explants or Circulating Tumor Cells (CTCs) with clinical outcomes have been largely unsuccessful.We present results from large cohort (n = 5090, three Arms) patients various solid organ tumors, where CRP Tumor-Associated (C-TACs) was determined against cancer-specific CCA panels generate database 56,466 unique CRP.In Arm 1 230), 93.7% concordance observed between C-TACs and concurrently obtained tissue Derived (TDCs). In arm 2 2201, pretreated), resistance ≥ 79% cases. blinded subset analysis 143 pretreated radiologically ascertained disease progression, 87% concordant vivo failure. 3 2734, therapy naïve), innate 61% 77 naïve patients, chemo-sensitivity response first line 97% cases.To our knowledge, this the expansive in-depth study demonstrating that real-time viable approach non-invasive assessment cancers.